Ritonavir Analogues as a Probe for Deciphering the Cytochrome P450 3A4 Inhibitory Mechanism

Author(s): Irina F. Sevrioukova, Thomas L. Poulos

Journal Name: Current Topics in Medicinal Chemistry

Volume 14 , Issue 11 , 2014

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Inactivation of human drug-metabolizing cytochrome P450 3A4 (CYP3A4) could lead to serious adverse events such as drug-drug interactions and toxicity. However, when properly controlled, CYP3A4 inhibition may be beneficial as it can improve clinical efficacy of co-administered therapeutics that otherwise are quickly metabolized by CYP3A4. Currently, the CYP3A4 inhibitor ritonavir and its derivative cobicistat are prescribed to HIV patients as pharmacoenhancers. Both drugs were designed based on the chemical structure/activity relationships rather than the CYP3A4 crystal structure. To unravel the structural basis of CYP3A4 inhibition, we compared the binding modes of ritonavir and ten analogues using biochemical, mutagenesis and x-ray crystallography techniques. This review summarizes our findings on the relative contribution of the heme-ligating moiety, side chains and the terminal group of ritonavir-like molecules to the ligand binding process, and highlights strategies for a structure-guided design of CYP3A4 inactivators.

Keywords: Crystal structure, CYP3A4, inhibitor design, ligand binding, pharmacophore, ritonavir analogues.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 02 June, 2014
Page: [1348 - 1355]
Pages: 8
DOI: 10.2174/1568026614666140506120647
Price: $65

Article Metrics

PDF: 28